New antibody shot aimed at taming hepatitis b
NCT ID NCT05856890
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a single dose of a new antibody (HepB mAb19) in 37 adults with chronic hepatitis B who are already on standard antiviral pills. The main goal is to see if the antibody is safe and how long it stays in the body. It is an early-phase trial, so it focuses on safety and drug levels, not yet on curing the infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
-
The Rockefeller University
RECRUITINGNew York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot that could shield healthcare workers from a silent killer
- Can a simple roadside test catch liver disease before it turns deadly?
- Hospital care model aims to treat opioid addiction and serious infections together
- Simple blood test aims to spot multiple cancers early
- Heart safety check for hepatitis b drug candidate
- Two-Drug combo aims to cure chronic hepatitis b